Investor Relations Corporate Profile Assembly Bio aspires to deliver innovative small molecule antiviral therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Minimum 15 minutes delayed. Source: LSEG Press Releases See all news Assembly Biosciences Highlights Presentations on Positive Phase 1b Data for ABI-5366 and ABI-1179 in Recurrent Genital Herpes at ESCMID Global 2026 Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes Events & Presentations See all upcoming events Dec 8, 2025 at 6:00 PM EST ABI-1179 and ABI-5366 Interim Phase 1b Results Update Nov 12, 2025 Guggenheim 2nd Annual Healthcare Innovation Conference – Fireside Chat Nov 7 - Nov 11, 2025 American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting 2025 Shareholder Tools Print Email Alerts RSS News Feeds Search Investors
Investor Relations Corporate Profile Assembly Bio aspires to deliver innovative small molecule antiviral therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Minimum 15 minutes delayed. Source: LSEG Press Releases See all news Assembly Biosciences Highlights Presentations on Positive Phase 1b Data for ABI-5366 and ABI-1179 in Recurrent Genital Herpes at ESCMID Global 2026 Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes Events & Presentations See all upcoming events Dec 8, 2025 at 6:00 PM EST ABI-1179 and ABI-5366 Interim Phase 1b Results Update Nov 12, 2025 Guggenheim 2nd Annual Healthcare Innovation Conference – Fireside Chat Nov 7 - Nov 11, 2025 American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting 2025
